Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review - Archive ouverte HAL
Article Dans Une Revue Current Treatment Options in Oncology Année : 2023

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review

Résumé

The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
Fichier non déposé

Dates et versions

hal-04294659 , version 1 (20-11-2023)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Tarek Assi, Carine Ngo, Matthieu Faron, Benjamin Verret, Antonin Lévy, et al.. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review. Current Treatment Options in Oncology, 2023, 24 (11), pp.1598-1613. ⟨10.1007/s11864-023-01139-3⟩. ⟨hal-04294659⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

More